[EN] QUINOLINYL GLUCAGON RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS DE QUINOLINYLGLUCAGON
申请人:PFIZER
公开号:WO2013014569A1
公开(公告)日:2013-01-31
The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.
Homogeneous Pd-catalyzed asymmetrichydrogenation of 3-phthalimido substituted quinolines was successfully developed, providing facile access to chiral substituted tetrahydroquinolines bearing two contiguous stereogenic centers with up to 90% ee.
An Investigation of the Reaction of 2-Aminobenzaldehyde Derivatives with Conjugated Nitro-olefins: An Easy and Efficient Synthesis of 3-Nitro-1,2-dihydroquinolines and 3-Nitroquinolines
作者:Ming-Chung Yan、Zhijay Tu、Chunchi Lin、Shengkai Ko、Jianming Hsu、Ching-Fa Yao
DOI:10.1021/jo030070z
日期:2004.3.1
prepared from the reaction of β-nitrostyrenes 2 and 2-aminobenzaldehyde 1 in the presence of DABCO. Not only β-nitrostyrenes but other alkyl nitro olefins also can be used in this reaction as well. When DDQ or silica gel was added to a solution of 3-nitro-1,2-dihydroquinolines 3, 3-nitro-2-substituted-quinolines 4 were obtained. When 2-aminobenzaldehyde derivatives 7 and 12 were reacted with β-nitrostyrenes
A Microwave-Assisted Facile One-Pot Synthesis of Annelated Pyridines from β-Formyl Enamides via Henry Reaction
作者:Romesh C. Boruah、Apurba Chetia、Moanochet Longchar、Kushal C. Lekhok
DOI:10.1055/s-2004-825595
日期:——
The base-catalysed solid phase condensation of β-formyl enamides with nitromethane under microwave irradiation afforded a novel one-pot synthesis of pyridines via Henry reaction.
The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R
1
, R
2
, R
3
, A
1
, A
2
, A
3
, B
1
, B
2
, B
3
and B
4
are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.